Ignite Creation Date:
2024-05-05 @ 5:00 PM
Last Modification Date:
2024-10-26 @ 9:27 AM
Study NCT ID:
NCT00368979
Status:
COMPLETED
Last Update Posted:
2018-09-26
First Post:
2006-08-24
Brief Title:
Dutasteride GI198745 In Benign Prostatic Hyperplasia Subjects
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
Clinical Evaluation of Dutasteride in Benign Prostatic Hyperplasia A Randomized Double-Blind Placebo-Controlled Parallel Group Comparative Study of GI198745 Dutasteride in Subjects With Benign Prostatic Hyperplasia
Status:
COMPLETED
Status Verified Date:
2018-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will assess the efficacy and safety of GI198745 05mg given once daily for 52 weeks to Benign Prostatic Hyperplasia BPH patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None